Ocugen’s OCU400 Phase 3 plus Korean licensing underpin potential 2026 BLA remains the company’s best bet at its first commercial gene therapy revenue. OCU410ST also received a Rare Pediatric Disease ...
A new genome-wide mapping method finally shows how thousands of genes connect to drive disease. Biomedical researchers are working intensively to identify the genes that contribute to disease, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback